Research ExplorerPublicationsComparison of estrogen and progesterone receptor status of c...

Comparison of estrogen and progesterone receptor status of circulating tumor cells and the primary tumor in metastatic breast cancer patients.

Standard

Comparison of estrogen and progesterone receptor status of circulating tumor cells and the primary tumor in metastatic breast cancer patients. / Aktas, Bahriye; Müller, Volkmar; Tewes, Mitra; Zeitz, Julia; Kasimir-Bauer, Sabine; Loehberg, Christian R; Rack, Brigitte; Schneeweiss, Andreas; Fehm, Tanja.

In: GYNECOL ONCOL, Vol. 122, No. 2, 2, 2011, p. 356-360.

Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review

Harvard

Aktas, B, Müller, V, Tewes, M, Zeitz, J, Kasimir-Bauer, S, Loehberg, CR, Rack, B, Schneeweiss, A & Fehm, T 2011, 'Comparison of estrogen and progesterone receptor status of circulating tumor cells and the primary tumor in metastatic breast cancer patients.', GYNECOL ONCOL, vol. 122, no. 2, 2, pp. 356-360. <http://www.ncbi.nlm.nih.gov/pubmed/21605893?dopt=Citation>

APA

Aktas, B., Müller, V., Tewes, M., Zeitz, J., Kasimir-Bauer, S., Loehberg, C. R., Rack, B., Schneeweiss, A., & Fehm, T. (2011). Comparison of estrogen and progesterone receptor status of circulating tumor cells and the primary tumor in metastatic breast cancer patients. GYNECOL ONCOL, 122(2), 356-360. [2]. http://www.ncbi.nlm.nih.gov/pubmed/21605893?dopt=Citation

Vancouver

Aktas B, Müller V, Tewes M, Zeitz J, Kasimir-Bauer S, Loehberg CR et al. Comparison of estrogen and progesterone receptor status of circulating tumor cells and the primary tumor in metastatic breast cancer patients. GYNECOL ONCOL. 2011;122(2):356-360. 2.

Bibtex

@article{d02646cd64e2485f830f7ea04a930fad,
title = "Comparison of estrogen and progesterone receptor status of circulating tumor cells and the primary tumor in metastatic breast cancer patients.",
abstract = "The expression of predictive markers including the estrogen (ER) and progesterone receptor (PR) expression can change during the course of the disease. Therefore, reassessment of these markers at the time of disease progression might help to optimize treatment decisions. Metastatic tissue may be difficult to obtain for repeated analysis. In this context, characterization of circulating tumor cells (CTCs) could be of relevance. It was the purpose of the present study (1) to reevaluate the ER/PR expression by CTCs and (2) to compare the hormone receptor status expression profile of CTCs with the primary tumor.",
keywords = "Humans, Female, Prospective Studies, Neoplasm Metastasis, Breast Neoplasms/*chemistry/pathology, Neoplastic Cells, Circulating/*chemistry, Receptor, erbB-2/analysis, Receptors, Estrogen/*analysis, Receptors, Progesterone/*analysis, Humans, Female, Prospective Studies, Neoplasm Metastasis, Breast Neoplasms/*chemistry/pathology, Neoplastic Cells, Circulating/*chemistry, Receptor, erbB-2/analysis, Receptors, Estrogen/*analysis, Receptors, Progesterone/*analysis",
author = "Bahriye Aktas and Volkmar M{\"u}ller and Mitra Tewes and Julia Zeitz and Sabine Kasimir-Bauer and Loehberg, {Christian R} and Brigitte Rack and Andreas Schneeweiss and Tanja Fehm",
year = "2011",
language = "English",
volume = "122",
pages = "356--360",
journal = "GYNECOL ONCOL",
issn = "0090-8258",
publisher = "Academic Press Inc.",
number = "2",

}

RIS

TY - JOUR

T1 - Comparison of estrogen and progesterone receptor status of circulating tumor cells and the primary tumor in metastatic breast cancer patients.

AU - Aktas, Bahriye

AU - Müller, Volkmar

AU - Tewes, Mitra

AU - Zeitz, Julia

AU - Kasimir-Bauer, Sabine

AU - Loehberg, Christian R

AU - Rack, Brigitte

AU - Schneeweiss, Andreas

AU - Fehm, Tanja

PY - 2011

Y1 - 2011

N2 - The expression of predictive markers including the estrogen (ER) and progesterone receptor (PR) expression can change during the course of the disease. Therefore, reassessment of these markers at the time of disease progression might help to optimize treatment decisions. Metastatic tissue may be difficult to obtain for repeated analysis. In this context, characterization of circulating tumor cells (CTCs) could be of relevance. It was the purpose of the present study (1) to reevaluate the ER/PR expression by CTCs and (2) to compare the hormone receptor status expression profile of CTCs with the primary tumor.

AB - The expression of predictive markers including the estrogen (ER) and progesterone receptor (PR) expression can change during the course of the disease. Therefore, reassessment of these markers at the time of disease progression might help to optimize treatment decisions. Metastatic tissue may be difficult to obtain for repeated analysis. In this context, characterization of circulating tumor cells (CTCs) could be of relevance. It was the purpose of the present study (1) to reevaluate the ER/PR expression by CTCs and (2) to compare the hormone receptor status expression profile of CTCs with the primary tumor.

KW - Humans

KW - Female

KW - Prospective Studies

KW - Neoplasm Metastasis

KW - Breast Neoplasms/chemistry/pathology

KW - Neoplastic Cells, Circulating/chemistry

KW - Receptor, erbB-2/analysis

KW - Receptors, Estrogen/analysis

KW - Receptors, Progesterone/analysis

KW - Humans

KW - Female

KW - Prospective Studies

KW - Neoplasm Metastasis

KW - Breast Neoplasms/chemistry/pathology

KW - Neoplastic Cells, Circulating/chemistry

KW - Receptor, erbB-2/analysis

KW - Receptors, Estrogen/analysis

KW - Receptors, Progesterone/analysis

M3 - SCORING: Journal article

VL - 122

SP - 356

EP - 360

JO - GYNECOL ONCOL

JF - GYNECOL ONCOL

SN - 0090-8258

IS - 2

M1 - 2

ER -